Table 1.
Baseline Characteristics
| Baseline Characteristic | Total HIV/HBV Cohort (N=94) | Subset Available for HBV Sequencinga (N=68) | Subset Unavailable for HBV Sequencinga (N=26) | p-valuea |
|---|---|---|---|---|
| Age | 32 (28–40) | 32 (28–40) | 35 (30–43) | 0.296 |
| Female | 56 (59.6%) | 42 (61.8%) | 14 (53.8%) | 0.484 |
| BMI, kg/m2 | 23.4 (20–26) | 23.8 (20.2–26) | 22.5 (19.4–26.8) | 0.302 |
| EtOH Use, Y | 25 (26.6%) | 20 (29.4%) | 5 (19.2%) | 0.318 |
| CD4+ T-cell/mm3 | 265 (167–401) | 265 (201–444) | 251 (126–340) | 0.267 |
| CD4+ T-cell ≤ 200 cells/mm3 | 27 (28.7%) | 17 (25%) | 10 (38.5%) | 0.197 |
| Log10 HIV RNA, copies/ml | 4.8 (4.2–5.4) | 4.8 (4.3–5.4) | 4.8 (4.1–5.3) | 0.355 |
| Log10 HBV DNA, IU/ml | 1.6 (0–5.5) | 1.6 (0–4.9) | 1.6 (0–6.7) | 0.266 |
| HBV DNA <2000 IU/ml | 63 (67%) | 48 (70.6%) | 15 (57.7%) | 0.234 |
| ALT, IU/ml | 24 (17–39) | 24 (15–39) | 26 (19–39) | 0.269 |
| HBeAgb Reactive | 19 (20.2%) | 13 (19.1%) | 6 (25%) | 0.541 |
| Liver Stiffness, kPa | 6.4 (4.7–8.7) | 6.1 (4.6–7.9) | 6.4 (4.7–9.8) | 0.627 |
| Cirrhosisc | 21 (22.3%) | 14 (20.6%) | 7 (26.9%) | 0.510 |
| Initiated ARTd | 81 (86.2%) | 57 (83.8%) | 24 (92.3%) | 0.286 |
Abbreviations: HIV, human immunodeficiency virus; HBV, hepatitis B virus; BMI, body-mass-index; EtOH, alcohol; ALT, alanine transaminase; HBeAg, hepatitis B e-antigen; ART, antiretroviral therapy
Continuous variables reported as median (IQR), categorical variables reported as number (%)
a
P-value comparing those patients with samples available for sequencing and those without samples available using Chi-Square for categorical variables and Mann-Whitney-U for continuous variables
b
Includes 5 samples with concurrent HBeAg and anti-HBe
c
Cirrhosis defined by baseline liver stiffness measurement ≥ 9.4 kPa
d
ART started after baseline liver stiffness measurement